Home Bratislava Medical Journal 2021 Bratislava Medical Journal Vol.122, No.2, p.132–137,2021

Journal info


Published Monthly, in English
Founded: 1919
ISSN 0006-9248
(E)ISSN 1336-0345

Impact factor 1.564


Aims and Scope
Editorial Info
Submission Guidelines

Select Journal

Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Bratislava Medical Journal Vol.122, No.2, p.132–137,2021

Title: Juglone can inhibit angiogenesis and metastasis in pancreatic cancer cells by targeting Wnt/β-catenin signaling
Author: F. Gokturk, D. Erkoc-Kaya, H. Arikoglu

Abstract: OBJECTIVES: We aimed to investigate the effects of juglone on angiogenesis, metastasis and cell proliferation processes in pancreatic cancer  (PC)  and to understand whether its possible effects occur via the Wnt signaling pathway by analyzing the expression levels of target genes of Wnt signaling.
BACKGROUND: PC is a silent and lethal cancer type which can only be detectable after metastasis and angiogenesis processes occured. The Wnt signaling pathway is one of the pathways that plays an active role in many biological processes in the cell. Mutations in the genes of this signaling pathway are related to the development of many cancers. Juglone, a natural compound, is shown to have cytotoxic and apoptotic effects on various cancer cells.
METHODS: PANC-1 and BxPC-3 pancreatic cancer cells were treated with juglone at RESULTS: Juglone seems to be able to inhibit angiogenesis and metastasis by affecting the activity of Wnt signaling target genes in human PC cell lines.
CONCLUSION: Juglone has a promising potential to develop new strategies for the treatment of PC (Tab. 2, Fig. 4, Ref. 35).

Keywords: pancreatic cancer, Wnt signaling pathway, juglone, anoikis
Published online: 26-Jan-2021
Year: 2021, Volume: 122, Issue: 2 Page From: 132, Page To: 137

download file

© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.